Xencor, Inc Equity Securities, FV-NI, Unrealized Gain (Loss)
Xencor, Inc (XNCR) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $18.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-05
- Xencor, Inc equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $18.06M, a 262.80% increase year-over-year.
- Xencor, Inc equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was -$51.93M, a 5618.49% decline year-over-year.
- Xencor, Inc equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was $41.99M.
- Xencor, Inc equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $44.21M, a 382.55% increase year-over-year.
- Xencor, Inc equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was $87.13M.
- Xencor, Inc equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$32.70M.
- Xencor, Inc equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was -$395.00K, a 101.69% decline from fiscal 2022.
- Xencor, Inc equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was $23.43M, a 11.65% increase from fiscal 2021.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $18.06M 10-Q · filed 2026-08-05 | -$33.87M 10-Q · filed 2026-08-05 | $8.13M derived: sum of 3 quarters · filed 2026-08-05 | $52.34M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | -$51.93M 10-Q · filed 2026-05-06 | -$9.94M derived: sum of 2 quarters · filed 2026-05-06 | $34.27M derived: sum of 3 quarters · filed 2026-05-06 | $39.25M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $41.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $86.20M derived: sum of 2 quarters · filed 2026-02-25 | $91.18M derived: sum of 3 quarters · filed 2026-08-05 | $87.13M 10-K · filed 2026-02-25 | ||
| 2025-09-30 | $44.21M 10-Q · filed 2025-11-05 | $49.19M derived: sum of 2 quarters · filed 2026-08-05 | $45.14M 10-Q · filed 2025-11-05 | $19.16M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $4.98M 10-Q · filed 2026-08-05 | $528.00K 10-Q · filed 2026-08-05 | -$25.05M derived: sum of 3 quarters · filed 2026-08-05 | -$15.89M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $941.00K 10-Q · filed 2026-05-06 | -$30.03M derived: sum of 2 quarters · filed 2026-05-06 | -$20.87M derived: sum of 3 quarters · filed 2026-05-06 | -$30.89M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | -$30.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$21.81M derived: sum of 2 quarters · filed 2026-02-25 | -$31.83M derived: sum of 3 quarters · filed 2026-02-25 | -$32.70M 10-K · filed 2026-02-25 | ||
| 2024-09-30 | $9.16M 10-Q · filed 2025-11-05 | -$853.00K derived: sum of 2 quarters · filed 2025-11-05 | -$1.73M 10-Q · filed 2025-11-05 | $14.71M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-06-30 | -$10.02M 10-Q · filed 2025-08-06 | -$10.53M 10-Q · filed 2025-08-06 | $5.55M derived: sum of 3 quarters · filed 2026-02-25 | -$5.47M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-03-31 | $2.33M 10-Q/A · filed 2025-02-24 | $15.56M derived: sum of 2 quarters · filed 2026-02-25 | $4.54M derived: sum of 3 quarters · filed 2026-02-25 | $4.83M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2023-12-31 | $13.24M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-25 | $2.21M derived: sum of 2 quarters · filed 2026-02-25 | $2.50M derived: sum of 3 quarters · filed 2026-02-25 | -$395.00K 10-K · filed 2026-02-25 | ||
| 2023-09-30 | -$11.02M 10-Q/A · filed 2025-02-24 | -$10.73M derived: sum of 2 quarters · filed 2025-02-24 | -$13.63M 10-Q/A · filed 2025-02-24 | $14.48M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $288.00K 10-Q/A · filed 2025-02-24 | -$2.61M 10-Q/A · filed 2025-02-24 | $25.50M derived: sum of 3 quarters · filed 2025-02-27 | $30.80M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | -$2.90M 10-Q/A · filed 2025-02-24 | $25.21M derived: sum of 2 quarters · filed 2025-02-27 | $30.51M derived: sum of 3 quarters · filed 2025-02-27 | $23.97M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $28.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $33.41M derived: sum of 2 quarters · filed 2025-02-27 | $26.86M derived: sum of 3 quarters · filed 2025-02-27 | $23.43M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $5.30M 10-Q · filed 2023-11-08 | -$1.25M derived: sum of 2 quarters · filed 2023-11-08 | -$4.68M 10-Q · filed 2023-11-08 | -$22.89M derived: sum of 4 quarters · filed 2025-02-24 | ||
| 2022-06-30 | -$6.54M 10-Q · filed 2023-08-03 | -$9.97M 10-Q · filed 2023-08-03 | -$28.19M derived: sum of 3 quarters · filed 2025-02-24 | -$26.69M derived: sum of 4 quarters · filed 2025-02-24 | ||
| 2022-03-31 | -$3.43M 10-Q · filed 2023-05-08 | -$21.65M derived: sum of 2 quarters · filed 2025-02-24 | -$20.14M derived: sum of 3 quarters · filed 2025-02-24 | $4.58M derived: sum of 4 quarters · filed 2025-02-24 | ||
| 2021-12-31 | -$18.22M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-02-24 | -$16.71M derived: sum of 2 quarters · filed 2025-02-24 | $8.01M derived: sum of 3 quarters · filed 2025-02-24 | $20.99M 10-K/A · filed 2025-02-24 | ||
| 2021-09-30 | $1.51M 10-Q · filed 2022-11-07 | $26.23M derived: sum of 2 quarters · filed 2022-11-07 | $39.21M 10-Q · filed 2022-11-07 | $38.52M derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-06-30 | $24.72M 10-Q · filed 2022-08-03 | $37.70M 10-Q · filed 2022-08-03 | $37.01M derived: sum of 3 quarters · filed 2023-02-27 | $39.78M derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-03-31 | $12.98M 10-Q · filed 2022-05-05 | $12.29M derived: sum of 2 quarters · filed 2023-02-27 | $15.06M derived: sum of 3 quarters · filed 2023-02-27 | $15.42M derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2020-12-31 | -$689.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $2.08M derived: sum of 2 quarters · filed 2023-02-27 | $2.44M derived: sum of 3 quarters · filed 2023-02-27 | $105.00K 10-K · filed 2023-02-27 | -$696.00K 10-K · filed 2021-02-24 | |
| 2020-09-30 | $2.77M 10-Q · filed 2021-11-08 | $2.80M 10-Q · filed 2020-11-06 | $3.13M derived: sum of 2 quarters · filed 2021-11-08 | $794.00K 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $358.00K 10-Q · filed 2021-08-04 | $300.00K 10-Q · filed 2020-08-05 | -$1.98M 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | -$2.34M 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |